Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

Rafei-Shamsabadi, David; Lehr, Saskia; Behrens, Max; Meiss, Frank

Rafei-Shamsabadi, David; Lehr, Saskia; Behrens, Max; Meiss, Frank.

Afiliação

Rafei-Shamsabadi D; Department of Dermatology and Venereology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.
Lehr S; Department of Dermatology and Venereology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.
Behrens M; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center-University of Freiburg, Zinkmattenstr. 6a, 79108 Freiburg, Germany.
Meiss F; Department of Dermatology and Venereology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.

Cancers (Basel) ; 14(3)2022 Jan 21.

Article em En | MEDLINE | ID: mdl-35158808

Palavras-chave

Interleukin-2; PD-1 inhibitor; combination therapy; intralesional; metastatic melanoma

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google